Results 171 to 180 of about 147,637 (252)

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas   +9 more
wiley   +1 more source

Management and long‐term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia‐related neuropathy: A single‐centre experience

open access: yesBritish Journal of Haematology, EarlyView.
In this 28‐patient retrospective cohort, rituximab‐based regimens for IgM‐related neuropathy yielded significant, sustained functional and neurological improvements over a 2‐year follow‐up. Furthermore, reductions in serum IgM levels correlated with improved Inflammatory Neuropathy Cause and Treatment disability scores, highlighting the long‐term ...
Maria Gavriatopoulou   +15 more
wiley   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

open access: yesBrain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu   +11 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy